China’s easing Covid norms to help non-life underwriting performance: AM Best
December 13 2022 by InsuranceAsia News
-
South Korea’s non-life insurance outlook stable on new regulations, strong P&C, motor results: AM Best
- November 15
In terms of challenges faced by the segment, AM Best highlighted slower expansion of auto insurance owing to recent rate cuts and sluggish growth in motor vehicle registrations as a key factor.
-
India’s Shriram General Insurance plans to list in 2-3 years: report
- November 7
The firm is also planning to re-enter the crop insurance market, seven years after it exited the business, and intends to reduce reliance on motor line.
-
Sompo, Bigmotor to investigate past claims frauds to compensate customers
- October 31
Bigmotor has changed its name to BALM following the scandal and is planning to announce a concrete recovery strategy for customers next month.
-
China’s EV transition to drive premium growth: Moody’s
- October 23
However, rising claims costs, higher accident rates and expensive components could erode the industry’s underwriting margins.
-
BHSI | Managing non-Asian exposure in long-tail lines
While US-exposed business can look attractive to Asian carriers, managing the volatility around the long-term results and the ability to model those losses are crucial, say BHSI’s Marc Breuil and Marcus Portbury.
-
Sedgwick | To Handle CAT Claims Well, Multi-Step Preparation is Key
When it comes to risk, it’s not a matter of “if” it’s a matter of “when” an event will occur.
-
HSBC Asset Management | Is it time to relook at Asian currency bonds?
With diversification and performance high on investors’ agendas, it seems a good time for global portfolios to revive allocations in Asian local currency bonds – including Hong Kong dollar (HKD) bonds.
-
PineBridge Investments | Why Asian insurers are exploring private credit and CLOs
The recent rollout of risk-based capital regimes across Asia calls for a closer alignment between insurers’ assets and liabilities. We explore potential ways to maintain a healthy investment yield and robust returns on regulatory capital.
